General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly. The Zacks Consensus Estimate for sales and earnings is pegged at $502.8 million ...

Get Instant Summarized Text (Gist) Radioiodine therapy after surgery increases relative survival rates in differentiated thyroid cancer patients across all risk groups. The greatest benefit is ...

Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver disease, according to findings in JAMA Internal Medicine.

It's well-known that a person's immune system wears down over time, becoming less effective as folks progress through middle age and become seniors. But that doesn't appear to hinder the ...

Hepatocellular carcinoma (HCC) accounts for more than 90% of instances ... The impact of ERX-315 on 6 well-established HCC cell lines was evaluated using the MTT and colony formation assays. The ...

We aim to develop non-viral nanocarriers to deliver ribonucleoproteins (RNP) targeting Glypican-3 (GPC3) and investigate the biological and immunological therapeutic effects from CRISPR-Cas9 GPC3 gene ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). The approval for use in advanced neuroendocrine tumors is ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...